Duration of Royalty Payments. 34 6.10 Maintenance of Royalty Records; Audit Rights ............... 34 6.11
Duration of Royalty Payments. With respect to Net Sales of any Product in any country in the Territory, royalties shall be paid hereunder with respect to Net Sales of such Product until [REDACTED] from the date of first commercial sale after Regulatory Approval of such Product in such country, but no longer than the duration of the Exclusive Period.
Duration of Royalty Payments. The royalties payable under this Section 4.4 shall be paid on a country-by-country basis on each Licensed Product until the expiration of the applicable Royalty Term.
Duration of Royalty Payments. Royalties under Article 6.2 shall be payable on a country by country basis for the longer of :
a) the life of ASTRAZENECA Patent Rights which are necessary to continue to manufacture, use or sell the Product in such country; or
b) a period of ten (10) years from Launch in that country (provided always that in the case of a country within the European Economic Area such ten (10) years period shall run from the date of Launch anywhere in the European Economic Area);
Duration of Royalty Payments. (a) Commencement All royalties payable hereunder shall be paid on a Country-by-Country basis from the date of first commercial sale of each Alliance Product in a particular Country and additionally, in the case of Sections 6.3.1 and 6.3.4, at such time as there is a Valid Claim of a Theravance Patent covering the Alliance Product sold.
(b) Duration of [*] Royalties Royalty obligations under Sections 6.3.1 and 6.3.4 in each Country of the Territory shall remain until the expiration or termination of the last Valid Claim of a Theravance Patent covering the Alliance Product in such Country.
(c) Duration of [*] Royalties Royalty obligations under Sections 6.3.2 and 6.3.5 in each Country of the Territory shall apply for a maximum period of fifteen (15) years from First Commercial Sale of the relevant Alliance Product in each such Country (where, for the avoidance of doubt, such period would include, and not be additional to, the time for which a full patent royalty was previously payable under either Section 6.3.1 or Section 6.3.4, as applicable).
(d) Duration of [*] Royalties Royalty obligations under Sections 6.3.3 and 6.3.6 in each Country of the Territory shall apply for a maximum period of ten (10) years from First Commercial Sale of the relevant Alliance Product in each such country.
Duration of Royalty Payments. The royalties payable by Merrimack to Dyax pursuant to Sections 4.6 and 4.7 shall be payable on a country-by-country and Product-by-Product basis for a period commencing with the First Commercial Sale and ending ten (10) years after First Commercial Sale; provided, however, in the event that such ten (10) years period for a Product in a particular country ends prior to the expiration of the last CAT Valid Claim in such country, then royalties shall be payable until the expiration of last CAT Valid Claim.
Duration of Royalty Payments. The royalties payable under Sections 5.2 and 5.3 shall be paid on each Royalty Bearing Product until the expiration of the applicable Royalty Term in the Territory. Upon the expiration of the Royalty Term applicable to any Royalty Bearing Product in the Territory, the Royalty-Paying Party’s licenses under Section 4.1 or 4.4, as applicable, with respect to such Royalty Bearing Product in the Territory shall convert to non-exclusive, fully paid-up, non-royalty-bearing licenses.
Duration of Royalty Payments. Pursuant to Section 4.4, Alcon shall pay to Pharmacyclics the royalties set forth in Section 4.4 on the Net Sales of each Licensed Product in the Territory on a country-by-country basis, for the longer of: (i) the last to expire of the Pharmacyclics Patent(s) which protect Alcon's exclusive sale of a Licensed Product in that country; or (ii) (*) after the First Commercial Sale of the Licensed Product.
Duration of Royalty Payments. Corregidor will pay the Royalties to Alkermes, as referenced in Section 5.2.1, for each Licensed Product, on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the expiration of the Alkermes Patents containing Valid Claims covering such Licensed Product in such country, or (ii) twelve (12) years and six (6) months after the Launch of such Licensed Product in such country.
Duration of Royalty Payments. Payments under Sections 5.7 and 5.8 above shall continue until the expiration of the Initial Royalty Term in such country for the Licensed Product concerned. After the Initial Royalty Term, Pfizer shall make payments to Quark [ * ] above until the expiration of the Extended Royalty Term in such country for the Licensed Product concerned; provided, however, Pfizer’s obligations to make any payments with respect to sales of Licensed Products in the Territory under Sections 5.7 and 5.8 above after the Initial Royalty Term shall expire when [ * ]. Upon expiration of the Royalty Term for a particular Licensed Product, Pfizer shall have a royalty-free, perpetual, irrevocable, worldwide, non-exclusive license, with the right to sublicense, under the Quark Technology to make, have made, use, sell, offer for sale and import such Biomolecule and such Licensed Product in the countries where the Royalty Term has expired.
